SYNOPSIS

- White acne is common in adolescents, the overall prevalence in adults may be increasing, especially among females.
- Acne in adult females is associated with greater negative impacts on quality of life, which along with increased acne severity in postpubertal years, may lead to greater healthcare utilization versus adult males.
- Additionally, adult females are more likely to have dry skin, which can increase the risk of cutaneous irritation associated with topical treatments.
- Combination therapies are recommended in the US for most patients; currently, recent meta-analyses showed that triple combinations are among the top two most effective treatments.
- With topical treatments, however, vehicle formulation can affect tolerability.

Combination therapy using adapalene, benzoyl peroxide, and clindamycin phosphate demonstrated good efficacy, safety, and tolerability in patients with moderate-to-severe acne.

OBJECTIVE

- To assess the impact of age on efficacy, safety, and tolerability in females with moderate-to-severe acne.

METHODS

- In one phase 2 (N=741; NCT03170388) and two identically designed phase 3 (N=183; NCT04214639; NCT04214652), double-blind, randomized, 12-week studies, patients aged ≥9 years with moderate-to-severe acne were randomized to receive CAB, clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel—have demonstrated good efficacy, safety, and tolerability in both younger and older females with moderate-to-severe acne.

- Half of CAB-treated females in both age groups achieved treatment success at week 12.

RESULTS

- The pooled population comprised a total of 395 females: aged 9-24 years (n=274); aged ≥25 years (n=121).
- Participants aged ≥9 years with moderate-to-severe acne were randomized to receive CAB, clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel; ITT, intent to treat; LS, least squares.

Efficacy

- In week 12 of both age groups, least squares percent improvement from baseline to week 12 was 29.6% for CAB gel versus 18.6% for vehicle gel (Table 1).
- Half of CAB-treated females in both age groups achieved treatment success at week 12 versus less than one-quarter with vehicle (P<0.001, both, Figure 2).
- Image showing acne improvements in CAB-treated females is shown in Figure 3.

Safety and Tolerability

- No notable age-related trends in safety or tolerability were observed (Table 2, Figure 4).
- Most TEAEs were mild to moderate in severity, with stepwise to the overall pooled phase 2 and 3 populations (overall CAB [N=382], Table 2).
- Tolerability in the entirety of cutaneous safety/tolerability assessments with CAB did not substantially differ between the older and younger females, with scores beginning to normal by week 6 (Figure 4).

CONCLUSIONS

- With greater than 75% lesion reductions and half of participants achieving treatment success by week 12, clindamycin phosphate 12%/adapalene 0.15%/benzoyl peroxide 3.1% gel demonstrated good efficacy, safety, and tolerability in both younger and older females with moderate-to-severe acne.

- No age-related trends in efficacy or tolerability were observed, suggesting that the innovative, fixed-dose, triple combination gel (approved for use in patients aged 12 and older) is a valuable treatment option for female patients of all ages, including those with more mature skin.

ACKNOWLEDGMENTS

Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics, Ortho Dermatologics is a division of Bausch Health US, LLC. Presented at 2024 Winter Clinical Dermatology Conference - Miami February 16-19, 2024

REFERENCES


AUTHOR DISCLOSURES

- Steven N. Skroza is a shareholder for Somabella Laboratories, LLC. She has served as a speaker for Aclaris and Ortho Dermatologics, consultant for Ortho Dermatologics and Aesthetics, Avava, Avita Medical, Beiersdorf, Cutera, Dermavant, Eirion Therapeutics, Eli Lilly, Galderma, Janssen, Jeune Aesthetics, and Quotient Research.
- Linda Stein Gold, MD, is a shareholder for Somabella Laboratories, LLC. She has served as a speaker for Aclaris and Ortho Dermatologics, consultant for Ortho Dermatologics and Aesthetics, Avava, Avita Medical, Beiersdorf, C."